Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-κB using in silico molecular docking

Cancer Letters

Volumn 291, Issue 2, 2010, Pages 217-224

  Law, Mary ^a   Corsino, Patrick ^a   Parker, Nicole Teoh ^a   Law, Brian K ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

IL 8; In silico molecular docking; NF B; p65; Serine 276; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; NSC 125186; NSC 127102; NSC 14322; NSC 1619; NSC 267467; NSC 72528; PROTEIN INHIBITOR; SERINE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA, COMPLEMENTARY; FEMALE; HUMANS; INTERLEUKIN-8; LIVER NEOPLASMS; NF-KAPPA B; PHOSPHOSERINE; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFECTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77950019662     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.10.015     Document Type: Article

References (31)

1. Karin M. Nuclear factor-κB in cancer development and progression. Nature 441 (2006) 431-436
2. Chen F., and Castranova V. Nuclear factor-κB, an unappreciated tumor suppressor. Cancer Res. 67 (2007) 11093-11098
3. Mukhopadhyay T., Roth J.A., and Maxwell S.A. Altered expression of the p50 subunit of the NF kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11 (1995) 999-1003
4. Bargou R.C., Leng C., Krappmann D., Emmerich R., Mapara M.Y., Bommert K., Royer H.D., Scheidereit C., and Dorken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 (1996) 4340-4347
5. Berger C., Brousset P., McQuain C., and Knecht H. Deletion variants within the NF-kappaB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leukemia Lymphoma 26 (1997) 239-250
6. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., and Sonenshein G.E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100 (1997) 2952-2960
7. Devalaraja M.N., Wang D.Z., Ballard D.W., and Richmond A. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res. 59 (1999) 1372-1377
8. Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville M.P., and Bours V. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 18 (1999) 2567-2577
9. Chen F., Lu Y., Zhang Z., Vallyathan V., Ding M., Castranova V., and Shi X. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J. Biol. Chem. 276 (2001) 11414-11419
10. Zhong H., Voll R.E., and Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1 (1998) 661-671
11. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., and Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22 (2003) 1313-1324
12. Anrather J., Racchumi G., and Iadecola C. Cis-acting element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J. Biol. Chem. 280 (2005) 244-252
13. Jamaluddin M., Wang S., Boldogh I., Tian B., and Brasier A.R. TNF-alpha-induced NF-kappaB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal. 19 (2007) 1419-1433
14. Nowak D.E., Tian B., Jamaluddin M., Boldogh I., Vergara L.A., Choudhary S., and Brasier A.R. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase9/cyclin T1 complexes. Mol. Cell. Biol. 28 (2008) 3623-3638
15. Gilmore T.D., and Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25 (2006) 6887-6899
16. Shoichet B.K., McGovern S.L., Wei B., and Irwin J.J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6 (2002) 439-446
17. Ofir R., Dwarki V.J., Rashid D., and Verma I.M. CREB represses transcription of fos promoter: role of phosphorylation. Gene Expression 1 (1991) 55-60
18. Zhong H., SuYang H., Erdjument-Bromage B., Tempst P., and Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89 (1997) 413-424
19. Sethi G., Ahn K.S., Sandur S.K., Lin X., Chaturvedi M.M., and Aggarwal B.B. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-κB signaling pathway. J. Biol. Chem. 281 (2006) 23425-23435
20. Joo J.H., and Jetten A.M. NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involved p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway. J. Biol. Chem. 283 (2008) 16391-16399
21. Makarov S.S. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol. Med. Today 6 (2000) 441-446
22. Courtois G., and Gilmore T.D. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 25 (2006) 6831-6843
23. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem. Pharmacol. 75 (2008) 1567-1679
24. Prasad R.C., Wang X.L., Law B.K., Davis B., Green G., Boone B., Sims L., and Law M. Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-κB. Cancer Lett. 275 (2009) 139-149
25. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montiminy M.R., and Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365 (1993) 855-859
26. Best J.L., Amezcua C.A., Mayr B., Flechner L., Murawsky C.M., Emerson B., Tsaffrir Z., Gardner K.H., and Montminy M. Identification of small-molecule antagonists that inhibit an activator-coactivator interaction. Proc. Natl. Acad. Sci. 101 (2004) 17622-17627
27. Luca M., Huang S., Gershenwald J.E., Singh R.K., Reich R., and Bar-Eli M. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151 (1997) 1105-1113
28. Xu L., and Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol. Res. 12 (2000) 97-106
29. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., Gudas J.M., and Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161 (2002) 125-134
30. B Ancrile B., O'Hayer K.M., and Counter C.M. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol. Interv. 8 (2008) 22-27
31. Lin K.Y., Lu D., Hung C.F., Peng S., Huang L., Jie C., Murillo F., Rowley J., Tsai Y.C., He L., Kim D.J., Jaffee E., Pardoll D., and Wu T.C. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res. 67 (2007) 1832-1841